公开(公告)号：US12050597B2

公开(公告)日：2024-07-30

申请号：US18078876

申请日：2022-12-09

Applicant: Splunk Inc.

Inventor： Amin Moshgabadi ,  Baibhav Gautam ,  Hema Krishnamurthy Mohan ,  Joshua Vertes

IPC: G06F16/00 ,  A61K39/245 ,  C12N7/00 ,  C12N9/10 ,  C12N9/12 ,  C12N9/16 ,  G06F3/0482 ,  G06F16/242 ,  G06F16/245 ,  G06F16/25 ,  A61K39/00

CPC classification number: G06F16/2428 ,  A61K39/245 ,  C12N7/00 ,  C12N9/1007 ,  C12N9/1241 ,  C12N9/16 ,  C12Y201/01056 ,  C12Y207/0705 ,  C12Y301/03033 ,  G06F3/0482 ,  G06F16/245 ,  G06F16/252 ,  A61K2039/53 ,  C07K2319/21 ,  C12N2710/16134

Abstract: An improved data intake and query system that can perform and display ingest-time and search-time field extraction, redaction, copy, and/or categorization is described herein. As described herein, ingest-time field extraction, redaction, copy, and/or categorization may refer to field or field value extraction, redaction, copy, and/or categorization that is performed by a log observer system of the data intake and query system on raw machine data as the raw machine data is ingested or received from a publisher. As described herein, search-time field extraction, redaction, copy, and/or categorization may refer to field or field value extraction, redaction, copy, and/or categorization that is performed by the log observer system and/or other components of the improved data intake and query system on historical raw machine data that has already been ingested and indexed by the improved data intake and query system.

公开(公告)号：US20230416705A1

公开(公告)日：2023-12-28

申请号：US18340083

申请日：2023-06-23

Applicant: New England Biolabs, Inc.

Inventor： Mehul Ganatra ,  Siu-hong Chan ,  Christopher H. Taron ,  G. Brett Robb

IPC: C12N9/16 ,  C12N9/12 ,  C12N9/10 ,  A61K39/245 ,  C12N7/00

CPC classification number: C12N9/16 ,  C12Y301/03033 ,  C12N9/1241 ,  C12Y207/0705 ,  C12N9/1007 ,  A61K39/245 ,  C12N7/00 ,  C12Y201/01056 ,  C12N2710/16134 ,  A61K2039/53

Abstract: The present disclosure relates to compositions, kits, and methods of making RNA vaccines having an appropriate cap structure. Systems, apparatus, compositions, and/or methods may include and/or use, in some embodiments, non-naturally occurring single-chain RNA capping enzymes. In some embodiments, an RNA capping enzyme may include an FCE variant having (a) an amino acid sequence at least 90% identical to positions 1 to 878 of SEQ ID NO: 1, and/or (b) one or more substitutions relative to SEQ ID NO: 1 at a position selected from positions corresponding to positions 215, 337, 572, 648, and 833 (e.g., a position selected from positions corresponding to position 215, 337, and 572) of SEQ ID NO: 1.

公开(公告)号：US11725196B2

公开(公告)日：2023-08-15

申请号：US17377797

申请日：2021-07-16

Applicant: New England Biolabs, Inc.

Inventor： Mehul Ganatra ,  Siu-hong Chan ,  Christopher H. Taron ,  G. B. Robb

IPC: C12N9/16 ,  A61K39/245 ,  C12N7/00 ,  C12N9/10 ,  C12N9/12 ,  A61K39/00 ,  C07K14/005

CPC classification number: C12N9/16 ,  A61K39/245 ,  C12N7/00 ,  C12N9/1007 ,  C12N9/1241 ,  C12Y201/01056 ,  C12Y207/0705 ,  C12Y301/03033 ,  A61K2039/53 ,  C07K2319/21 ,  C12N2710/16134

Abstract: The present disclosure relates to compositions, kits, and methods of making RNA vaccines having an appropriate cap structure. Systems, apparatus, compositions, and/or methods may include and/or use, in some embodiments, non-naturally occurring single-chain RNA capping enzymes. In some embodiments, an RNA capping enzyme may include an FCE variant having (a) an amino acid sequence at least 90% identical to positions 1 to 878 of SEQ ID NO: 1, and/or (b) one or more substitutions relative to SEQ ID NO: 1 at a position selected from positions corresponding to positions 215, 337, 572, 648, and 833 (e.g., a position selected from positions corresponding to position 215, 337, and 572) of SEQ ID NO: 1.

公开(公告)号：US20230227881A1

公开(公告)日：2023-07-20

申请号：US18154437

申请日：2023-01-13

Applicant: CureVac SE

Inventor： Tilmann ROOS ,  Benyamin YAZDAN PANAH ,  Markus CONZELMANN ,  Andreas THESS ,  Dominik BUOB ,  Martin KUNZE ,  Veronika WAGNER

IPC: C12P19/34 ,  C12N9/10 ,  C12N9/16 ,  C12N9/12 ,  C12N11/02 ,  C12N11/087 ,  C12N11/098

CPC classification number: C12P19/34 ,  C12N9/1007 ,  C12Y201/01057 ,  C12Y201/01056 ,  C12Y301/03033 ,  C12N9/16 ,  C12Y207/0705 ,  C12N9/1241 ,  C12N11/02 ,  C12N11/087 ,  C12N11/098

Abstract: The present invention relates to an immobilized capping enzyme, preferably an immobilized Vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2′-O-methyltransferase, preferably an immobilized Vaccinia virus cap-specific nucleoside 2′-O-methyltransferase. Moreover, the present invention relates to a method for immobilizing said enzymes and to a method of using said enzymes for the addition of a 5′-cap structure to RNAs. Moreover, the present invention relates to an enzyme reactor for performing the capping reaction using said immobilized enzymes and the subsequent separation of the 5′-capped RNA product. In addition, the present invention relates to a kit comprising the capping enzyme and/or the cap-specific nucleoside 2′-O-methyltransferase.

公开(公告)号：US09540671B2

公开(公告)日：2017-01-10

申请号：US14598874

申请日：2015-01-16

Applicant: EUKARYS

Inventor： Philippe Jais

IPC: C12N9/14 ,  C12P19/34 ,  C12N9/10 ,  C12N9/12 ,  A61K38/00

CPC classification number: C12P19/34 ,  A61K38/00 ,  C07K2319/00 ,  C12N9/1007 ,  C12N9/1241 ,  C12N9/1247 ,  C12N9/14 ,  C12Y201/01056 ,  C12Y306/04013 ,  Y02A50/411 ,  Y02A50/469

Abstract: The invention provides a chimeric enzyme comprising at least one catalytic domain of a RNA triphosphatase, at least one catalytic domain of a guanylyltransferase, at least one catalytic domain of a N7-guanine methyltransferase, and at least one catalytic domain of a DNA-dependant RNA polymerase. The invention also provides pharmaceutical composition comprising said chimeric enzyme and uses of said chimeric enzyme.

Abstract translation: 本发明提供了包含至少一种RNA三磷酸酶的催化​​结构域，鸟苷酰基转移酶的至少一个催化结构域，N7-鸟嘌呤甲基转移酶的至少一个催化结构域和至少一个DNA依赖性RNA的催化结构域的嵌合酶 聚合酶。 本发明还提供了包含所述嵌合酶的药物组合物和所述嵌合酶的用途。

公开(公告)号：US08962292B2

公开(公告)日：2015-02-24

申请号：US13641584

申请日：2011-04-15

Applicant: Philippe Jais

Inventor： Philippe Jais

IPC: C12N15/73 ,  C12N9/12 ,  C12N9/10 ,  C12N9/14 ,  A61K38/00

CPC classification number: C12P19/34 ,  A61K38/00 ,  C07K2319/00 ,  C12N9/1007 ,  C12N9/1241 ,  C12N9/1247 ,  C12N9/14 ,  C12Y201/01056 ,  C12Y306/04013 ,  Y02A50/411 ,  Y02A50/469

Abstract: The invention provides a chimeric enzyme comprising at least one catalytic domain of a RNA triphosphatase, at least one catalytic domain of a guanylyltransferase, at least one catalytic domain of a N7-guanine methyltransferase, and at least one catalytic domain of a DNA-dependant RNA polymerase. The invention also provides pharmaceutical composition comprising said chimeric enzyme and uses of said chimeric enzyme.

Abstract translation: 本发明提供了包含至少一种RNA三磷酸酶的催化​​结构域，鸟苷酰基转移酶的至少一个催化结构域，N7-鸟嘌呤甲基转移酶的至少一个催化结构域和至少一个DNA依赖性RNA的催化结构域的嵌合酶 聚合酶。 本发明还提供了包含所述嵌合酶的药物组合物和所述嵌合酶的用途。

公开(公告)号：US20140363876A1

公开(公告)日：2014-12-11

申请号：US14471649

申请日：2014-08-28

Applicant: CELLSCRIPT, LLC

Inventor： Jerome Jendrisak ,  Ronald Meis ,  Gary Dahl

IPC: C12P19/34

CPC classification number: C12P19/34 ,  C12N9/1007 ,  C12N9/1241 ,  C12N15/1072 ,  C12N15/1075 ,  C12N15/1096 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/317 ,  C12N2320/51 ,  C12Y201/01056 ,  C12Y201/01057 ,  C12Y207/07019 ,  C12Y207/0705

Abstract: The present invention relates to kits and methods for efficiently generating 5′ capped RNA having a modified cap nucleotide and for use of such modified-nucleotide-capped RNA molecules. In particular, the present invention provides kits and methods for capping RNA using a modified cap nucleotide and a capping enzyme system, such as poxvirus capping enzyme. The present invention finds use for in vitro production of 5′-capped RNA having a modified cap nucleotide and for in vitro or in vivo production of polypeptides by in vitro or in vivo translation of such modified-nucleotide-capped RNA. The invention also provides methods and kits for capturing or isolating uncapped RNA comprising primary RNA transcripts or RNA having a 5′-diphosphate, and methods and kits for using a capping enzyme system and modified cap nucleotides for labeling uncapped RNA comprising primary RNA transcripts or RNA having a 5′-diphosphate with detectable dye or enzyme moieties.

公开(公告)号：US20070281336A1

公开(公告)日：2007-12-06

申请号：US11787352

申请日：2007-04-16

Applicant: Jerome Jendrisak ,  Ronald Meis ,  Gary Dahl

Inventor： Jerome Jendrisak ,  Ronald Meis ,  Gary Dahl

IPC: C12P19/34 ,  C07H21/00 ,  C07H21/02 ,  C12N5/04 ,  C12P21/00 ,  C12N5/10 ,  C12N9/00 ,  C12N9/10

CPC classification number: C12P19/34 ,  C12N9/1007 ,  C12N9/1241 ,  C12N15/1072 ,  C12N15/1075 ,  C12N15/1096 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/317 ,  C12N2320/51 ,  C12Y201/01056 ,  C12Y201/01057 ,  C12Y207/07019 ,  C12Y207/0705

Abstract: The present invention relates to kits and methods for efficiently generating 5′ capped RNA having a modified cap nucleotide and for use of such modified-nucleotide-capped RNA molecules. The invention is used to obtain novel compositions of such modified-nucleotide-capped RNA molecules. In particular, the present invention provides kits and methods for capping RNA using a modified cap nucleotide and a capping enzyme system, such as poxvirus capping enzyme. The present invention finds use for in vitro production of 5′-capped RNA having a modified cap nucleotide and for in vitro or in vivo production of polypeptides by in vitro or in vivo translation of such modified-nucleotide-capped RNA for a variety of research, therapeutic, and commercial applications. The invention also provides methods and kits for capturing or isolating uncapped RNA comprising primary RNA transcripts or RNA having a 5′-diphosphate, such as RNA synthesized in vitro or obtained from a biological source, including prokaryotic mRNA that is in a mixture with other prokaryotic and/or eukaryotic nucleic acids. The method for capturing modified-nucleotide-capped RNA also provides methods and kits for obtaining only type-specific or condition-specific modified-nucleotide-capped RNA by cap-dependent subtraction of that portion of the captured modified-nucleotide-capped RNA in cells of one type or condition that is the same as RNA in cells of another type or condition. The invention further provides methods and kits for using a capping enzyme system and modified cap nucleotides for labeling uncapped RNA comprising primary RNA transcripts or RNA having a 5′-diphosphate with detectable dye or enzyme moieties.

Abstract translation: 本发明涉及用于有效产生具有修饰的帽核苷酸的5'封端RNA并用于这种经修饰的核苷酸封端的RNA分子的试剂盒和方法。 本发明用于获得这种经修饰的核苷酸封端RNA分子的新组合物。 特别地，本发明提供了使用修饰的帽核苷酸和封端酶系统（例如痘病毒覆盖酶）对RNA进行封端的试剂盒和方法。 本发明用于体外生产具有修饰的帽核苷酸的5'上限的RNA，并且通过体外或体内翻译这些经修饰的核苷酸封端的RNA进行多种研究，体外或体内产生多肽 ，治疗和商业应用。 本发明还提供用于捕获或分离未包封的RNA的方法和试剂盒，其包含初级RNA转录物或具有5'-二磷酸的RNA，例如在体外合成或从生物来源获得的RNA，包括与其他原核生物混合的原核mRNA 和/或真核的核酸。 用于捕获修饰的核苷酸加帽的RNA的方法还提供用于仅通过Cap依赖性减去细胞中捕获的修饰核苷酸加帽的RNA的那部分获得仅特定类型或条件特异性修饰的核苷酸加帽的RNA的方法和试剂盒 与另一类型或病症细胞中的RNA相同的一种类型或病症。 本发明还提供了使用封端酶系统和修饰的帽核苷酸标记未封端RNA的方法和试剂盒，其包含具有可检测染料或酶部分的具有5'-二磷酸的初级RNA转录物或RNA。